Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

DOI: 10.1016/j.cell.2021.02.033

Authors: Piyada Supasa (The Wellcome Centre for Human Genetics, University of Oxford) , Daming Zhou (The Wellcome Centre for Human Genetics, University of Oxford) , Wanwisa Dejnirattisai (The Wellcome Centre for Human Genetics, University of Oxford) , Chang Liu (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Alexander J. Mentzer (The Wellcome Centre for Human Genetics, University of Oxford; Oxford University Hospitals NHS Foundation Trust) , Helen M. Ginn (Diamond Light Source) , Yuguang Zhao (The Wellcome Centre for Human Genetics, University of Oxford) , Helen M. E. Duyvesteyn (The Wellcome Centre for Human Genetics, University of Oxford) , Rungtiwa Nutalai (The Wellcome Centre for Human Genetics, University of Oxford) , Aekkachai Tuekprakhon (The Wellcome Centre for Human Genetics, University of Oxford) , Beibei Wang (The Wellcome Centre for Human Genetics, University of Oxford) , Guido Paesen (The Wellcome Centre for Human Genetics, University of Oxford) , Jose Slon-Campos (The Wellcome Centre for Human Genetics, University of Oxford) , César López-Camacho (The Wellcome Centre for Human Genetics, University of Oxford) , Bassam Hallis (Public Health England (PHE)) , Naomi Coombes (Public Health England (PHE)) , Kevin Bewley (Public Health England (PHE)) , Sue Charlton (Public Health England (PHE)) , Thomas S. Walter (The Wellcome Centre for Human Genetics, University of Oxford) , Eleanor Barnes (Oxford University Hospitals NHS Foundation Trust; NIHR Oxford Biomedical Research Centre) , Susanna J. Dunachie (Oxford University Hospitals NHS Foundation; University of Oxford; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok) , Donal Skelly (Oxford University Hospitals NHS Foundation Trust; University of Oxford) , Sheila F. Lumley (University of Oxford) , Natalie Baker (Public Health England (PHE)) , Imam Shaik (Public Health England (PHE)) , Holly Humphries (Public Health England (PHE)) , Kerry Godwin (Public Health England (PHE)) , Nick Gent (Public Health England (PHE)) , Alex Sienkiewicz (Public Health England (PHE)) , Christina Dold (NIHR Oxford Biomedical Research Centre; University of Oxford) , Robert Levin (Worthing Hospital) , Tao Dong (University of Oxford) , Andrew J. Pollard (NIHR Oxford Biomedical Research Centre; University of Oxford) , Julian C. Knight (The Wellcome Centre for Human Genetics, University of Oxford; Oxford University Hospitals NHS Foundation Trust) , Paul Klenerman (Oxford University Hospitals NHS Foundation Trust; NIHR Oxford Biomedical Research Centre; University of Oxford) , Derrick Crook (University of Oxford) , Teresa Lambe (Jenner Institute, University of Oxford) , Elizabeth Clutterbuck (NIHR Oxford Biomedical Research Centre; University of Oxford) , Sagida Bibi (NIHR Oxford Biomedical Research Centre; University of Oxford) , Amy Flaxman (Jenner Institute, University of Oxford) , Mustapha Bittaye (Jenner Institute, University of Oxford) , Sandra Belij-Rammerstorfer (Jenner Institute, University of Oxford) , Sarah Gilbert (Jenner Institute, University of Oxford) , Dave R. Hall (Diamond Light Source) , Mark Williams (Diamond Light Source) , Neil G. Paterson (Diamond Light Source) , William James (University of Oxford) , Miles W. Carroll (The Wellcome Centre for Human Genetics, University of Oxford; Public Health England (PHE)) , Elizabeth E. Fry (The Wellcome Centre for Human Genetics, University of Oxford) , Juthathip Mongkolsapaya (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford; Mahidol University) , Jingshan Ren (University of Oxford) , David I. Stuart (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford; Diamond Light Source; Instruct-ERIC) , Gavin R. Screaton (The Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Cell

State: Published (Approved)
Published: February 2021
Diamond Proposal Number(s): 27009

Abstract: SARS-CoV-2 has caused over 2M deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbours 9 amino-acid changes in the spike, including N501Y in the ACE2 interacting-surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterised monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.

Diamond Keywords: Viruses; COVID-19

Subject Areas: Biology and Bio-materials, Medicine


Instruments: I03-Macromolecular Crystallography

Discipline Tags:

Life Sciences & Biotech Health & Wellbeing Infectious Diseases Pathogens Vaccines Structural biology Chemistry Biochemistry

Technical Tags: